Question

Should there be a new accounting standard specific to the pharmaceutical industry (in IAS or AASB)...

Should there be a new accounting standard specific to the pharmaceutical industry (in IAS or AASB) to resolve the discrepancies in identifying R&D effectively?

and why?

Homework Answers

Answer #1

ANSWER.

NO NEED FOR A NEW ACCOUNTING STANDARD SPECIFIC TO THE PHARMACEUTICAL INDUSTRY .

REASONS :

IFRS CLEARLY GIVE DIRECTIONS FOR TREATMENT OF R & D COSTS FOR PHARMACEUTICAL COPMPANIES.

R& D EXPENSES INCURRED IN RESEARCH PHASE SHOULD BE EXPENSED AS AND WHEN INCURED AND THOSE INCURRED DURING DEVELOPMENT PHASE SHOULD BE CAPITALISED ON MEETING THE CRITERIA SET FORTH.

IF ANY R&D EXPENSES ARE NOT POSSIBLE TO CLASSIFY AS ABOVE , THEN THEY SHOULD BE TREATED AS INCURRED ON RESEARCH PHASE AND CHARGED TO PROFIT AND LOSS ACCOUNT.

Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
relating to IAS / AASB Discuss the nature of new drug development that may necessitate specific...
relating to IAS / AASB Discuss the nature of new drug development that may necessitate specific accounting guidance, explaining where clarity is most needed.
When should a company in the extractive industry start accounting for its restoration costs? (4 marks)...
When should a company in the extractive industry start accounting for its restoration costs? using Australian Accounting Standard System. ( AASB )
Please identify a specific company that would rely on managerial accounting information and why this is...
Please identify a specific company that would rely on managerial accounting information and why this is the case. When identifying the company please list it’s full legal name, location, industry, and how managerial accounting would assist in analyzing a company’s financials. It is not allowed to use the same company as a student from a previous post in Week 1.
Devise a strategy for a potential new entrant into the Turkish airline industry, using ideas from...
Devise a strategy for a potential new entrant into the Turkish airline industry, using ideas from the course. Please avoid broad, vague clichés. Be as specific as you possibly can. Relate the principles and techniques we have covered throughout the course to this industry. Discuss why the incumbent players cannot respond effectively to your proposed strategy.
Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the...
Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the appropriate production facilities. When Gama-Smith acquires a stake in a development project, it makes an initial payment to the other pharmaceutical company. It then makes a series of further stage payments until the drug development is complete and it has been approved by the relevant authorities. In the financial statements for the year ended 30 June 2019, Gama-Smith has treated the different stakes in...
The pharmaceutical industry often comes under fire, especially during times of a pandemic, like the COVID-19...
The pharmaceutical industry often comes under fire, especially during times of a pandemic, like the COVID-19 outbreak we are seeing right now. This is because the sector has become a sort of poster child for the patent system – a firm invests a large amount of time and money into developing a drug, which eventually saves lives, but in return it gets to be the monopoly seller of this drug for 20 years. To put some specific figures on it,...
Case Analysis: Valeant Pharmaceuticals is a specialty drug manufacturer operating in the fast-cycle pharmaceutical industry. In...
Case Analysis: Valeant Pharmaceuticals is a specialty drug manufacturer operating in the fast-cycle pharmaceutical industry. In this business, size often matters and Valeant, along with most of the major players in the industry, has aggressively utilized mergers and acquisitions to acquire R&D capabilities and other key strategic resources, create synergies, capture market share, and use acquired legacy products to support future growth. Valeant’s 2010 merger with Biovail Corp was designed with all of these benefits in mind. To develop an...
A pharmaceutical manufacturer is concerned that the impurity concentration in pills should not exceed 3%. It...
A pharmaceutical manufacturer is concerned that the impurity concentration in pills should not exceed 3%. It is known that from a particular production run impurity con- centrations follow a normal distribution with a standard deviation of 0.4%. A random sample of 64 pills from a production run was checked, and the sample mean impurity concentration was found to be 3.07%. a. Test at the 5% level the null hypothesis that the population mean impurity concentration is 3% against the alternative...
Sheila McGrave, a well-known equity analyst for the pharmaceutical industry, has gathered data for Medsonic, Inc.,...
Sheila McGrave, a well-known equity analyst for the pharmaceutical industry, has gathered data for Medsonic, Inc., and it is presented in Table 1 below. Table 1: Data for Medsonic, Inc. Income statement: Sales $7,200,000 - Cash operating expenses -6,000,000 - Research and development expenses -250,000 - Depreciation expense -230,000 EBIT $720,000 -Interest expense -120,000 EBT $600,000 -Taxes -240,000 Net income $360,000 Other data: Current liabilities-non-interest bearing $1,000,000 Current liabilities-interest bearing $500,000 Long-term debt $1,500,000 Common equity $3,000,000 Total assets $6,000,000...
Rector Public Accounting concluded that completion times for audits should be fairly standard. Ten audits are...
Rector Public Accounting concluded that completion times for audits should be fairly standard. Ten audits are selected from all five of Rector’s storefront offices. Based on the results shown here, construct and interpret an R-chart and X-chart to determine whether completion times are in control. Sample               1      2      3      4      5                                4.1      10.5    9.7      7.8     15.7                                3.2      15.0   11.9      9.5      8.9                                3.6      6.0     12.0     6.9      7.8                                5.6      9.0      5.8      5.8      7.6                                6.3      8.0      6.9     ...